Curaleaf Holdings (CURA) AI Stock Analysis

• Market Cap: $2.62B
• Dividend Yield: N/A
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.31
• Revenue Growth: -2.64%
• EPS Growth: 1.65%
• Country: CA
• Employees: 5,519
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.08
• Shares Outstanding: 670,695,300
• 10 Day Avg. Volume: 709,555
• 30 Day Avg. Volume: 1,030,416
• PEG Ratio: 0.57
• Price to Book (P/B): 1.34
• Price to Sales (P/S): 0.86
• P/FCF Ratio: 17.94
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 1.76
• Enterprise Value/Gross Profit: 3.61
• Enterprise Value/Ebitda: 10.27
• 1Y Price Target: $4.49
• Price Target Upside: 24.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: C$3.50 ▼(-3.31% Downside)

Curaleaf Holdings' overall stock score is primarily impacted by its financial performance challenges, including declining revenues and cash flow issues. While technical analysis shows positive momentum, the valuation metrics are poor due to negative earnings. The earnings call provides a mixed outlook with strong international growth but significant domestic and regulatory challenges.

Positive Factors

Negative Factors

Curaleaf Holdings Business Overview & Revenue Model

Company Description

Curaleaf Holdings, Inc. is a leading vertically integrated cannabis operator in the United States, focused on the production and sale of cannabis products for both medical and adult-use markets. The company operates cultivation, processing, and retail facilities across several states, offering a wide range of products including flower, edibles, tinctures, and topicals. Curaleaf is committed to providing high-quality cannabis products and enhancing the consumer experience through its multiple retail locations and e-commerce platforms.

How the Company Makes Money

Curaleaf generates revenue primarily through the sale of cannabis products in its dispensaries. This includes a diverse product range comprising dried flower, pre-rolls, edibles, concentrates, and topicals, which cater to both medical and recreational consumers. The company's revenue model is supported by its vertically integrated operations, allowing it to control production costs and quality. Additionally, Curaleaf benefits from strategic partnerships and collaborations with other cannabis brands and companies, enhancing its product offerings and market presence. The company's expansion into new states and markets, along with its emphasis on compliance and regulatory adherence, also contribute significantly to its earnings.

Curaleaf Holdings Financial Statement Overview

Summary

Curaleaf Holdings faces significant financial challenges, with declining revenues, negative profitability, and cash flow constraints. While the balance sheet shows moderate leverage, the company's inability to generate positive returns and cash flow is a major concern for its financial health.

Income Statement

Curaleaf Holdings has experienced declining revenue growth with a negative trend in net profit margins, indicating challenges in maintaining profitability. The gross profit margin remains moderate, but EBIT and EBITDA margins have shown volatility, reflecting operational inefficiencies.

Balance Sheet

The company has a balanced debt-to-equity ratio close to 1, suggesting moderate leverage. However, the negative return on equity indicates that the company is not generating sufficient returns on shareholders' equity, which is a concern for investors.

Cash Flow

Curaleaf's cash flow situation is concerning, with negative free cash flow growth and low operating cash flow coverage ratios. The free cash flow to net income ratio indicates that the company struggles to convert earnings into free cash flow, highlighting liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.34B	1.35B	1.34B	1.21B	626.64M
Gross Profit	625.61M	639.25M	614.45M	579.03M	687.59M	390.51M
EBITDA	220.14M	233.14M	238.76M	220.97M	278.98M	128.59M
Net Income	-244.34M	-215.42M	-281.20M	-376.93M	-109.13M	-61.33M
Balance Sheet
Total Assets	2.92B	2.95B	3.10B	3.41B	3.11B	2.39B
Cash, Cash Equivalents and Short-Term Investments	102.27M	93.03M	91.82M	163.18M	299.33M	73.54M
Total Debt	843.02M	853.82M	883.55M	931.91M	652.40M	577.71M
Total Liabilities	1.98B	1.96B	1.93B	2.01B	1.44B	1.01B
Stockholders Equity	871.30M	861.21M	1.05B	1.28B	1.55B	1.38B
Cash Flow
Free Cash Flow	49.54M	64.42M	5.05M	-91.96M	-205.92M	-113.92M
Operating Cash Flow	136.37M	162.57M	75.26M	46.40M	-33.96M	12.36M
Investing Cash Flow	-87.48M	-93.83M	-78.69M	-228.62M	-163.97M	-197.11M
Financing Cash Flow	-37.76M	-54.24M	-67.02M	50.54M	424.80M	224.08M

Curaleaf Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CURA, the sentiment is Positive. The current price of 3.62 is below the 20-day moving average (MA) of 3.94, above the 50-day MA of 2.99, and above the 200-day MA of 1.95, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 51.02 is Neutral, neither overbought nor oversold. The STOCH value of 22.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CURA.

Curaleaf Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	69 Neutral	1.36B	54.57	1.71%	―	31.72%	0.00%
CURA	56 Neutral	$2.62B	―	-24.93%	―	-2.64%	1.65%
TRUL	56 Neutral	1.83B	-8.24	-13.60%	―	4.92%	-64.84%
CL	55 Neutral	599.70M	-7.98	-10.28%	―	-5.65%	73.45%
ACB	51 Neutral	388.97M	-21.17	-3.65%	―	28.42%	48.33%
WEED	50 Neutral	639.30M	-0.46	-104.81%	―	-4.24%	55.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Curaleaf Holdings Corporate Events

Curaleaf Expands Internationally Amidst Strong Q2 2025 Performance

Curaleaf Holdings reported a second-quarter 2025 revenue of $315 million, with a notable 62% year-over-year growth in its international segment. The company was awarded a license to operate in Turkey, marking a significant expansion in its international operations. Despite a net loss, Curaleaf is focusing on strategic growth, including opening new retail locations, launching innovative products, and strengthening its leadership team to position itself for future industry growth.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf to Announce Q2 2025 Financial Results

Curaleaf Holdings announced it will release its second quarter 2025 financial and operational results on August 6, 2025, after market close. The announcement will be followed by a conference call and webcast, providing stakeholders with insights into the company’s performance and strategic direction. This release is significant for stakeholders as it offers an opportunity to gauge Curaleaf’s market positioning and operational progress in the evolving cannabis industry.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Acquires Full Ownership of European Operations

Curaleaf Holdings has acquired the remaining equity stake in Curaleaf International Holdings Limited from a strategic institutional investor, bringing its ownership to 100%. This acquisition, completed through a Put/Call Option agreement, allows Curaleaf to streamline decision-making and enhance strategic alignment across its European operations, reinforcing its commitment to international expansion and long-term shareholder value.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Strengthens Leadership with New President and Key Executive Hires

Curaleaf Holdings has appointed Rahul Pinto as the new President to lead its global commercial functions, alongside strengthening its leadership team with three new Senior Vice Presidents in digital, retail merchandising, and brand marketing. This strategic move aims to enhance Curaleaf’s position as a global leader in the cannabis industry by leveraging Pinto’s extensive experience in consumer packaged goods and retail, as well as the expertise of the new hires, to drive innovation and growth.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Confirms Board and Auditor at 2025 AGM

Curaleaf Holdings, Inc. recently held its 2025 Annual General Meeting of Shareholders, where key resolutions were passed, including the election of ten directors and the reappointment of PKF O’Connor Davies, LLP as the company’s auditor. The meeting, conducted via webcast, saw significant shareholder participation with over 1.7 billion votes cast. These decisions are expected to reinforce Curaleaf’s governance and operational strategies, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.

Curaleaf Holdings Strengthens Governance at 2025 Annual Meeting

Curaleaf Holdings, Inc. held its 2025 Annual General Meeting of Shareholders via webcast, where key resolutions were passed, including the election of directors and the reappointment of the company’s auditor. The meeting saw a significant number of votes cast, reflecting strong shareholder engagement. These developments are expected to reinforce Curaleaf’s governance and operational stability, positively impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$6.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page.